(CercleFinance.com) – Eli Lilly announces the presentation of several studies at the congress of the European Society of Medical Oncology (ESMO) which will be held in Madrid from October 20 to 24.
In a last-minute oral presentation, the laboratory will notably present the five-year results of Verzénio (abemaciclib) collected as part of a phase III trial. The trial evaluates two years of adjuvant treatment with Verzenio in combination with endocrine therapy (ET) versus ET alone in certain breast cancers (EBC) at high risk of recurrence.
Additionally, in two late-breaking oral presentations Eli Lilly will share interim analysis results from Phase 3 clinical studies evaluating Retevmo versus platinum-based chemotherapy – with or without pembrolizumab – as initial treatment for patients with non-small cell lung cancer (NSCLC) with RET fusion positive.
Finally, the laboratory will also present clinical data on the immunoestrant in monotherapy and combined therapy. These results include the first clinical data on immunoestrant in combination with everolimus or alpelisib in certain breast cancers.
Copyright © 2023 CercleFinance.com. All rights reserved.
Did you like this article ? Share it with your friends using the buttons below.
